Funding for this research was provided by:
Canadian Institutes of Health Research (MOP-123338, PJT-165943, PJT-156449, PJT-148550, MOP-110992)
Juvenile Diabetes Research Foundation International (3-APF-2018-586-A-N, 3-PDF-2014-191-A-N)
Received: 28 March 2020
Accepted: 11 February 2021
First Online: 23 February 2021
Ethics approval and consent to participate
: All animal procedures were approved by the Animal Care Committees at the University of British Columbia and Université Laval and carried out in accordance with the Canadian Council on Animal Care guidelines. Procedures using human islets were approved by and performed in accordance with guidelines of the Clinical Research Ethics Board of the University of British Columbia.
: Not applicable.
: HCD is a scientific advisor for and owns restricted shares in Integrated Nanotherapeutics. CBV is a director of and owns restricted shares in Integrated Nanotherapeutics. SM, SSL and FP have no potential conflicts to disclose.